⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Savara Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Savara Inc.
↗Yardley, PA, USA
Savara Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative, inhaled therapies for rare respiratory diseases. The company leverages its proprietary NanoCluster formulation technology to create advanced pulmonary drug delivery solutions, aiming to address significant unmet medical needs in patient populations with limited treatment options.
Its primary focus is the development of MOLBREEVI (molgramostim inhalation solution), a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 clinical development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company operates as a public entity and maintains a strategic focus on orphan drug development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:SVRA
Market Cap:$1.13B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Recombinant protein, Inhaled therapy
Active Trials:38
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Grifols (Inhaled liposomal ciprofloxacin development)
COMPETITION
Position:Niche Player
Competitors:Vertex Pharmaceuticals, TFF Pharmaceuticals
LEADERSHIP
Key Executives:
Not specified - CEO
LINKS
Website:savaraphara.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Savara Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.